Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 11/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20801484 | 1.00 | NAAA (0.40) | NAAASMN1; SMN2S1PR5EPHX1PSMB8 | |
| SCHEMBL21664445 | 0.86 | NAAA (0.49) | NAAAEPHX1PSMB8ASAH1 | |
| SCHEMBL20801422 | 0.85 | NAAA (0.51) | NAAAEPHX1ASAH1 | |
| SCHEMBL22181049 | 0.85 | NAAA (0.51) | NAAAEPHX1ASAH1 | |
| SCHEMBL24860007 | 0.85 | NAAA (0.51) | NAAAEPHX1ASAH1 | |
| SCHEMBL18779827 | 0.85 | NAAA (0.51) | NAAAEPHX1ASAH1 | |
| SCHEMBL24622843 | 0.85 | NAAA (0.47) | NAAAEPHX1PSMB8ASAH1 | |
| SCHEMBL24593481 | 0.84 | L3MBTL1 (0.41) | NAAASMN1; SMN2PSMB8 | |
| SCHEMBL9752033 | 0.84 | L3MBTL1 (0.41) | NAAASMN1; SMN2PSMB8 | |
| SCHEMBL19698794 | 0.84 | ALOX12 (0.35) | SMN1; SMN2PSMB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11547761-B1 | Antibody adjuvant conjugates | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11547761-B1 | Antibody adjuvant conjugates | FCGR1A, FCGR3B, FCGR2A | NAAA 1169/4885SMN1; SMN2 4460/4885S1PR5 2071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.